MARKET IS CLOSED
Loading latest tickers...

Market Indices

S&P 500
$7,801.77
-0.22%
NASDAQ 100
$31,160.08
-0.21%
DOW JONES
$51,180.00
-0.66%
NASDAQ Composite
$27,538.69
-0.22%
RUSSELL 2000
$2,777.00
-1.29%
CBOE VIX
$15.08
+0.47%

Sector Heatmap

Technology-0.30%
Financials-0.48%
Healthcare+1.03%
Consumer Cycl-0.32%
Consumer Staples-0.12%
Energy-0.58%
Industrials-2.18%
Materials-1.51%
Real Estate-1.29%
Utilities-0.02%
Comm Services-0.35%

PRLD — Prelude Therapeutics Incorporated

Nasdaq

Prelude Therapeutics Incorporated

CompareBack to Screener
$3.83
+0.02(+0.52%)
O
3.84
H
3.93
L
3.69
V
454.55K
⏱️ End-of-day dataAs of Oct 7, 2026
OverviewStatisticsFinancialsHistorical DataOptionsDividend HistoryNewsChart

Chart

About PRLD

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateSep 25, 2020
Employees79
Stock ExchangeNasdaq
Ticker SymbolPRLD
Websitehttps://www.preludetx.com

Key Financial Statistics

Market Cap$292.88M
P/E RatioN/A
Dividend YieldNone
EPSN/A
BetaN/A
52-Week Range$1.15 - $6.83
52-Week Avg Volume688.6K
VWAP$3.82
Transactions4,798
Total Recorded Bars1,516 days